Association of APOE ε4 genotype and lifestyle with cognitive function among Chinese adults aged 80 years and older: A cross-sectional study.
Age Factors
Aged, 80 and over
Alcohol Drinking
/ adverse effects
Apolipoprotein E4
/ genetics
Apolipoproteins E
/ genetics
Body Weight
China
/ epidemiology
Cognition
Cognitive Aging
Cognitive Dysfunction
/ diagnosis
Cross-Sectional Studies
Diet
/ adverse effects
Exercise
Feeding Behavior
Female
Gene-Environment Interaction
Genotype
Health Surveys
Healthy Lifestyle
Humans
Life Style
Male
Protective Factors
Risk Assessment
Risk Factors
Risk Reduction Behavior
Smoking
/ adverse effects
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
25
05
2020
accepted:
25
03
2021
entrez:
1
6
2021
pubmed:
2
6
2021
medline:
5
10
2021
Statut:
epublish
Résumé
Apolipoprotein E (APOE) ε4 is the single most important genetic risk factor for cognitive impairment and Alzheimer disease (AD), while lifestyle factors such as smoking, drinking, diet, and physical activity also have impact on cognition. The goal of the study is to investigate whether the association between lifestyle and cognition varies by APOE genotype among the oldest old. We used the cross-sectional data including 6,160 oldest old (aged 80 years old or older) from the genetic substudy of the Chinese Longitudinal Healthy Longevity Survey (CLHLS) which is a national wide cohort study that began in 1998 with follow-up surveys every 2-3 years. Cognitive impairment was defined as a Mini-Mental State Examination (MMSE) score less than 18. Healthy lifestyle profile was classified into 3 groups by a composite measure including smoking, alcohol consumption, dietary pattern, physical activity, and body weight. APOE genotype was categorized as APOE ε4 carriers versus noncarriers. We examined the associations of cognitive impairment with lifestyle profile and APOE genotype using multivariable logistic regressions, controlling for age, sex, education, marital status, residence, disability, and numbers of chronic conditions. The mean age of our study sample was 90.1 (standard deviation [SD], 7.2) years (range 80-113); 57.6% were women, and 17.5% were APOE ε4 carriers. The mean MMSE score was 21.4 (SD: 9.2), and 25.0% had cognitive impairment. Compared with those with an unhealthy lifestyle, participants with intermediate and healthy lifestyle profiles were associated with 28% (95% confidence interval [CI]: 16%-38%, P < 0.001) and 55% (95% CI: 44%-64%, P < 0.001) lower adjusted odds of cognitive impairment. Carrying the APOE ε4 allele was associated with 17% higher odds (95% CI: 1%-31%, P = 0.042) of being cognitively impaired in the adjusted model. The association between lifestyle profiles and cognitive function did not vary significantly by APOE ε4 genotype (noncarriers: 0.47 [0.37-0.60] healthy versus unhealthy; carriers: 0.33 [0.18-0.58], P for interaction = 0.30). The main limitation was the lifestyle measurements were self-reported and were nonspecific. Generalizability of the findings is another limitation because the study sample was from the oldest old in China, with unique characteristics such as low body weight compared to populations in high-income countries. In this study, we observed that healthier lifestyle was associated with better cognitive function among the oldest old regardless of APOE genotype. Our findings may inform the cognitive outlook for those oldest old with high genetic risk of cognitive impairment.
Sections du résumé
BACKGROUND
Apolipoprotein E (APOE) ε4 is the single most important genetic risk factor for cognitive impairment and Alzheimer disease (AD), while lifestyle factors such as smoking, drinking, diet, and physical activity also have impact on cognition. The goal of the study is to investigate whether the association between lifestyle and cognition varies by APOE genotype among the oldest old.
METHODS AND FINDINGS
We used the cross-sectional data including 6,160 oldest old (aged 80 years old or older) from the genetic substudy of the Chinese Longitudinal Healthy Longevity Survey (CLHLS) which is a national wide cohort study that began in 1998 with follow-up surveys every 2-3 years. Cognitive impairment was defined as a Mini-Mental State Examination (MMSE) score less than 18. Healthy lifestyle profile was classified into 3 groups by a composite measure including smoking, alcohol consumption, dietary pattern, physical activity, and body weight. APOE genotype was categorized as APOE ε4 carriers versus noncarriers. We examined the associations of cognitive impairment with lifestyle profile and APOE genotype using multivariable logistic regressions, controlling for age, sex, education, marital status, residence, disability, and numbers of chronic conditions. The mean age of our study sample was 90.1 (standard deviation [SD], 7.2) years (range 80-113); 57.6% were women, and 17.5% were APOE ε4 carriers. The mean MMSE score was 21.4 (SD: 9.2), and 25.0% had cognitive impairment. Compared with those with an unhealthy lifestyle, participants with intermediate and healthy lifestyle profiles were associated with 28% (95% confidence interval [CI]: 16%-38%, P < 0.001) and 55% (95% CI: 44%-64%, P < 0.001) lower adjusted odds of cognitive impairment. Carrying the APOE ε4 allele was associated with 17% higher odds (95% CI: 1%-31%, P = 0.042) of being cognitively impaired in the adjusted model. The association between lifestyle profiles and cognitive function did not vary significantly by APOE ε4 genotype (noncarriers: 0.47 [0.37-0.60] healthy versus unhealthy; carriers: 0.33 [0.18-0.58], P for interaction = 0.30). The main limitation was the lifestyle measurements were self-reported and were nonspecific. Generalizability of the findings is another limitation because the study sample was from the oldest old in China, with unique characteristics such as low body weight compared to populations in high-income countries.
CONCLUSIONS
In this study, we observed that healthier lifestyle was associated with better cognitive function among the oldest old regardless of APOE genotype. Our findings may inform the cognitive outlook for those oldest old with high genetic risk of cognitive impairment.
Identifiants
pubmed: 34061824
doi: 10.1371/journal.pmed.1003597
pii: PMEDICINE-D-20-02310
pmc: PMC8168868
doi:
Substances chimiques
ApoE protein, human
0
Apolipoprotein E4
0
Apolipoproteins E
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1003597Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: XJ and ZN were employees MindRank AI ltd.. The other authors have no conflicts of interest.
Références
Neuron. 2009 Aug 13;63(3):287-303
pubmed: 19679070
Int J Geriatr Psychiatry. 2016 Dec;31(12):1345-1353
pubmed: 26891153
Am J Geriatr Psychiatry. 2006 Feb;14(2):139-44
pubmed: 16473978
Neurosci Lett. 2014 Jul 25;576:17-21
pubmed: 24887584
Nat Commun. 2018 May 29;9(1):2098
pubmed: 29844566
Alzheimers Dement. 2007 Jul;3(3):186-91
pubmed: 19595937
Eur J Prev Cardiol. 2020 Feb 07;:
pubmed: 33611408
Comput Methods Programs Biomed. 2005 Jan;77(1):1-9
pubmed: 15639705
Epidemiology. 2013 Jul;24(4):490-9
pubmed: 23676264
Nat Med. 2019 Sep;25(9):1364-1369
pubmed: 31451782
Sci Transl Med. 2011 Jun 29;3(89):89ra57
pubmed: 21715678
JAMA Neurol. 2018 Apr 1;75(4):462-470
pubmed: 29356827
Lancet Neurol. 2005 Nov;4(11):705-11
pubmed: 16239176
BMJ. 2004 Sep 4;329(7465):539
pubmed: 15304383
J Nutr Health Aging. 2012;16(9):754-8
pubmed: 23131816
J Neurol. 2014 Jan;261(1):66-72
pubmed: 24146255
J Prev Alzheimers Dis. 2016 Mar;3(1):53-64
pubmed: 26900574
BMJ Open. 2019 Jan 25;9(1):e022846
pubmed: 30782689
Adv Nutr. 2016 Sep 15;7(5):889-904
pubmed: 27633105
Sci Rep. 2014 Mar 17;4:4383
pubmed: 24632849
Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):457-69
pubmed: 23558489
J Gerontol B Psychol Sci Soc Sci. 2006 Mar;61(2):S107-15
pubmed: 16497961
Aging (Albany NY). 2020 Jan 3;12(1):309-317
pubmed: 31899685
Age Ageing. 2016 Jul;45(4):511-7
pubmed: 27103599
Dement Geriatr Cogn Disord. 2006;22(1):99-107
pubmed: 16710090
Int J Environ Res Public Health. 2019 Aug 09;16(16):
pubmed: 31404951
Prev Med. 2009 Jan;48(1):86-90
pubmed: 19026677
Ann Neurol. 2010 Jan;67(1):114-21
pubmed: 20186856
Mol Psychiatry. 2015 Feb;20(2):183-92
pubmed: 25644384
Aging Ment Health. 2003 Jul;7(4):308-15
pubmed: 12888443
Arch Gen Psychiatry. 2012 Jun;69(6):627-35
pubmed: 22309970
JAMA. 2019 Aug 06;322(5):430-437
pubmed: 31302669
China Economic J. 2012;5(2-3):131-149
pubmed: 24443653
Ann Neurol. 1990 Apr;27(4):428-37
pubmed: 2353798
Alzheimers Dement. 2015 Jun;11(6):718-26
pubmed: 26045020
Mol Psychiatry. 2014 Jan;19(1):76-87
pubmed: 23207651
Nutr J. 2017 Sep 11;16(1):56
pubmed: 28893250
JAMA. 2015 Aug 25;314(8):781-90
pubmed: 26305648
Sci Rep. 2016 Feb 25;6:21243
pubmed: 26912274
Mech Ageing Dev. 2017 Jul;165(Pt B):86-97
pubmed: 28040447
Hum Biol. 1995 Apr;67(2):195-215
pubmed: 7729825
Nat Rev Neurol. 2018 Nov;14(11):653-666
pubmed: 30291317
JAMA. 2014 Apr 9;311(14):1406-15
pubmed: 24682252
Sci Rep. 2020 Jan 9;10(1):82
pubmed: 31919381
Can J Cardiol. 2015 May;31(5):613-9
pubmed: 25843167
Subst Abuse Treat Prev Policy. 2006 Mar 29;1:8
pubmed: 16722525